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Abstract Glomerular kidney disease is a major healthcare
burden and considered to represent a sum of disorders that
evade a refined and effective treatment. Excellent biological
and genetic studies have defined pathways that go awry in
podocytes, which are the regulatory cells of the glomerular
filter. The question now is how to define targets for novel
improved therapies. In this review, we summarize critical
points around targeting the TRPC6 channel in podocytes.
Keywords Glomerular disease.Focal segmental
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Introduction
Glomerular kidney diseases continue to affect an increasing
number of patients around the world. An early sign of these
disorders is loss of protein into the urine [1]. Studies on the
mechanisms of proteinuria have focused in particular on
podocytes, which are cells in the glomeruli that line the
capillaries and constitute a major part of the filtration
apparatus by providing foot processes with interconnected
slit diaphragms (SDs). While it has become clear that
proteinuria is almost inevitably associated with podocyte
injury, as evidenced by disruption of the SD and effacement
of foot processes, it is still not clear which best approaches
would be to reconstitute normal podocyte function and to
repair the damaged filtration barrier. When searching for the
pharmaceutical targets in cells, the accessibility of the target
cell, the target itself, and the signals that are modified by
interfering with the target have all to be taken into account
[2]. The TRPC6 ion channel has attracted special attention
because not only are there gain-of function mutations in the
TRPC6 gene in a subset of hereditary glomerular disorders,
such as familial focal segmental glomerulosclerosis
(FSGS), but it is also induced in its non-mutant form under
a wide variety of acquired glomerular diseases [3]. In
addition, TRPC6 is also an interacting protein at the
podocyte SD [4] and thus located at an accessible site
where drugs can reach TRPC6 before and after passing
through the SD. Thus, TRPC6 in podocytes would appear
to be the ideal target for small molecules or biological
modifiers—once they become available.
Role of podocytes in the regulation of glomerular
filtration
Renal function entails the ultra-filtration of blood in the
glomeruli, which operates as a sieve that is permeable to
water and small solutes while largely excluding macro-
molecules on the basis of size and charge by retaining them
in the blood. The glomerular filtration barrier comprises
several elements, including a fenestrated capillary endothe-
lium, a triple-layered glomerular basement membrane
(GBM), and a population of highly specialized cells called
podocytes. Mesangial cells, which are inside the GBM, also
play a role in regulating glomerular tuft stability and
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TRPC channel modulation in podocytes—inching toward
novel treatments for glomerular diseasesustained glomerular function by participating in signaling
exchange with podocytes [5].
Podocytes and in particular their adjacent foot processes
are connected by specialized cell junctions referred to as slit
diaphragms (SDs) [6–8]. These cells have attracted increas-
ing attention because of their recognized role in glomerular
pathology [9]. The biology of the adhesion and signaling
molecule nephrin has turned out to be crucial for proper
functioning of the SD [8]. This observation followed a
series of important studies showing that defects in nephrin
protein expression or in the nephrin gene can lead to severe
proteinuria as part of an autosomal recessive congenital
nephrotic syndrome. Nephrin is a transmembrane molecule
with an intracellular signaling domain, a transmembrane
domain, and a large ectodomain consisting of eight Ig
motifs and one type III fibronectin domain. The ectodomain
is long enough that two nephrin molecules can undergo a
homophilic interaction in trans; consequently, they are
sufficient to help keep the SD wide enough [8]. The genetic
disruption of nephrin unravels its important role in keeping
foot processes apart from each other. The results of nephrin
inactivation are narrowed and dysfunctional filtration slits
that soon thereafter lead to complete foot process efface-
ment [10, 11]. Moreover, signaling through this system
enables recruitment of a number of other molecules,
including Nck and CD2-associated protein, which can then
modulate the behavior of the underlying cytoskeleton [12].
Other critical components of the SD, such as Neph1,
Neph2, podocin, and the ion channel TRPC6, have also
been shown to play critical roles in glomerular filtration and
in podocyte signaling by providing scaffold and mechano-
sensitive properties to the filtration site [4].
TRPC channels in podocytes
There are seven functional members of the TRPC channel
family in mice (TRPC1–7) and six in humans, with TRPC2
being a pseudogene [13, 14]. The TRPC channels are
members of a larger channel family known as TRP
channels, which have a broad role in chemo- and
mechanosensation and in allowing cells to sense changes
in their local environment [13, 15]. TRPC channels can
heteromerize and thereby have the potential to form a very
large number of unique channels [14].
Minimally functional TRPC channels are tetrameric
proteins composed of subunits with six transmembrane
segments and NH2- and COOH-termini facing the cytosol
[14] (Fig. 1). A series of ankyrin repeats are present in the
NH2-terminal, and all of the TRPC channels have a highly
conserved 25-residue TRP domain immediately attached to
the COOH-terminal side of the last transmembrane seg-
ment, which includes a proline-rich domain known as TRP
box 2. The ankyrin repeats and the TRP box 2 are domains
for protein interactions. The presence of a calmodulin and
inositol 1,4,5-trisphosphate receptor-binding region (CIRB
region) has also been described in the COOH-terminal of
TRPC channels [16, 17]. Calmodulin-binding domains
have been identified in both the NH2-a n dC O O H -
terminals of some TRPC members, including TRPC6
[18]. The pore–loop domain is located between the fifth
and sixth transmembrane segments [19], and TRPC
channels are permeable to monovalent and divalent cations.
The mechanisms underlying the activation of TRPC
channels are highly controversial and depend on whether or
not the channels are part of a heteromeric complex
containing other TRPC members, scaffolding proteins, or
even members of other ion channel families [20].
Mutations in the TRPC6 gene cause FSGS
The discovery of TRPC6 mutations as a cause for familial
FSGS has opened new areas of investigation [4, 21]. While
TRPC6 gene mutations are inherited in an autosomal
Fig. 1 Structure of the TRPC6 monomer and location of mutations.
TRPC6 belongs to the large family of TRP channels containing six
transmembrane domains. Four subunits are required to assemble a
functional channel. Subunits can combine with other TRPC channels.
The TRPC6 in podocytes is part of the slit diaphragm (SD)
multiprotein complex. Mutations in the TRPC6 gene are located on
the N-terminal and C-terminal sites. All known mutations are gain-of-
function mutations. Ank Ankyrin repeat, cc coiled–coiled domain,
CIRB CaM/IP3R-binding domain
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FSGS is not restricted to certain ethnic groups. TRPC6
mutations were found to cosegregate with kidney disease in
families of African-American, Colombian, Polish, Mexican,
and Irish/German descent alike [4, 21] and appeared to
account for a significant number of inherited FSGS cases.
In the study by Reiser and colleagues [4], 71 families with
familial FSGS were tested, and five turned out to be
positive for TRPC6 mutations, pointing to a relative
frequency of TRPC6-related FSGS of approximately 7%
of all cases of familial FSGS. The age range at disease
presentation was broad, ranging from 16 to 61 years. As
such TRPC6-related FSGS can be classified as a disease
with a rather late onset, which is in contrast to other genetic
glomerulopathies that often manifest in infancy, such as
congenital nephrotic syndrome of the Finnish type [22],
steroid-resistant nephrotic syndrome of the podocin type
[23], or Wilms’ tumor protein 1 (WT1)-related diseases
[24].
While the early onset in these diseases is due to the
severe damage that is inflicted on the molecular architecture
of the SD and the process of glomerular filtration, the
question remains why the onset of kidney disease in
patients with TRPC6 mutations occurs years into life. One
possible explanation is that mutations in TRPC6 may
produce subtle changes in intracellular function that lead
to irreversibly altered cell behavior only after time and in
the presence of other renal insults (second hit hypothesis)
(Fig. 2). This would be similar to the adult onset and
dominantly inherited form of FSGS due to mutations in the
widely expressed protein α-actinin-4 [25]. In addition,
podocytes express several TRPC channel subunits other
than TRPC6 [20], and partial functional redundancy may
also help account for the late onset of glomerular disease.
Indeed, the ability of TRPC6 to form heteromers with other
TRPC channels suggests a complex cellular regulation of
calcium homeostasis [26].
Interestingly, patients with TRPC6-related FSGS do not
present with any other pathological phenotype. TRPC6
protein is widely expressed in smooth muscle cells, where it
is thought to contribute to the regulation of airway
resistance and vascular tone [27]. However, TRPC6
mutations appear to exhibit their deleterious effects mainly
in the kidney. These observations suggest that the glomer-
ular phenotype is the consequence of a unique role of
TRPC6 in the functional organization of the glomerular
filtration barrier and the increased susceptibility of an
imperfectly regulated filtration apparatus due to TRPC6
mutations. In this context, TRPC6 belongs to the same
category of genes as α-actinin-4 and CD2AP. Mutations in
both genes lead foremostly to glomerular kidney disease
while being widely expressed and associated with a
plethora of different cellular functions in many cells
throughout the body [25, 28]. In the case of CD2AP, it is
possible to rescue lethality in CD2AP
-/- mice with
podocyte-targeted expression of CD2AP, highlighting the
particular role of CD2AP protein in podocytes [29].
Nature of TRPC6 mutations
All known mutations map to the terminal domains of the
TRPC6 protein (Fig. 1). Six N-terminal missense muta-
tions (G109S, P112Q, M132T, N125S, N143S, and
S270T) locate in or near ankyrin repeats and an adjacent
lipid/trafficking domain. The ankyrin domains drive self-
association of TRPC homomers [30], whereas the lipid-
binding domain binds DAG and thus controls transloca-
tion of the channel to the plasma membrane [31]. A
recently identified mutation L780P is near the EWKFAR
motif that is conserved in all TRP channels, whereas four
additional mutations (K874*, Q889K, R895C, and
E 8 9 7 K )m a pt oap r e d i c t e dc o i l e d –coil domain at the
C-terminus [32].
In TRPC channels, the first ankyrin-like repeat is the
minimum indispensable key structure for the functional
assembly of homo- and heteromeric TRPC4/TRPC5 chan-
Fig. 2 Podocyte TRPC function in health and disease and associated
therapies. Normal TRPC6 gene and protein function (in green) allows
for a physiological regulation of the kidney filtration barrier. Mutated
TRPC6, such as in hereditary focal segmental glomerulosclerosis
(FSGS)( in blue), is associated with decreased adaptive capacities of
podocytes and late-onset (within years) glomerular disease. Increased
expression of wild-type TRPC6 protein (in orange) is found in
acquired glomerular diseases, such as membranous nephropathy (MN)
and secondary FSGS. ARB Angiotensin II receptor blocker, ACE-I
angiotensin converting enzyme inhibitor, HTN hypertension
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mise the ability of TRPC6 to oligomerize with other TRPC
subunits or to interact with other binding partners. Ankyrin
repeats have also been shown to be important determinants
of the proper plasma membrane targeting of TRPC
channels [33, 34]. Whereas not all ankyrin repeats seem
to be crucial for the functional assembly of TRPC channels,
a truncated variant of TRPC3 lacking all of the N-terminal
ankyrin repeats was found to no longer mediate agonist-
induced Ca
2+-entry in HEK293 cells [33]. Finally, muta-
tions within the ankyrin repeats of TRPC6 may prevent the
channel from being correctly inserted into the plasma
membrane. This hypothesis is supported by findings of
Cayouette et al. suggesting that TRPC6 levels at the plasma
membrane are regulated by targeted membrane insertion
[35].
Notably, no changes in peak current amplitude were
detected for the N-terminal N143S and S270T mutations
and for the K874Stop non-sense mutation [4]. These do,
however, display an increased opening time and thus
transport more current per opening [36]. Additional factors
involved may include altered channel regulation (despite
normal current amplitude), altered interaction with SD
proteins, and/or altered protein turnover.
Among the three mutations at the C-terminus identified
by Reiser et al. [4] two (R895C; E897K) are located very
close to each other in a putative coiled–coil domain. The
coiled–coil is an ubiquitous protein motif that is commonly
used for oligomerization. There is one potential coiled–coil
motif in each of the cytosolic – and C-termini of TRPCs.
While no study has specifically investigated the importance
of the C-terminal coiled–coil motif in the TRPC channel,
the results of a recent study suggest that the C-terminal tail
of TRPC4 and TRPC6 participates in channel oligomeriza-
tion [37]. Importantly, the R895C and E897K mutations
both resulted in TRPC6 channels with higher current
amplitudes, suggesting that disruption of the C-terminal
putative coiled–coil motif in TRPC6 has a direct conse-
quence on channel activity. Whether this is indeed due to an
interference with the ability of TRPC6 to oligomerize with
other channel subunits will have to be addressed in future
studies.
As is the case for the N143S and S270T mutations, the
mutation identified by Winn et al. in a large family from
New Zealand (P112Q) is also located at the N-terminal
intracellular tail in the sequence region spanning the four
ankyrin repeats [21]. Similar to the increased channel
activity that is observed for the R895C and E897K
mutations, Winn et al. found the current amplitude
increased for the TRPC6 P112Q channel [21], indicating
that interference with both the N– and C-terminal domains
of TRPC6 can give rise to hyperactive channels. They also
provide a possible explanation for the increased current
amplitude caused by the P112Q mutation: based on the
results of their surface biotinylation studies, they dem-
onstrated that mutant TRPC6 channels were more
abundant in the plasma membrane when expressed
heterologously in HEK293 cells than their wild-type
counterparts. Interestingly, Heeringa and colleagues de-
scribed a mutation in the N-terminus of TRPC6 M132T
that leads to FSGS disease in children. These authors
found that the channel activity of M132T increased
largely with augmented peak current as well as delayed
inactivation [36]. This finding supports the notion that
calcium-dose effects mediated by TRPC6 might play a
role in determining the onset and severity of disease.
Clearly, more studies are required to explore this
concept.
Consequences of TRPC6 for the diagnosis of FSGS
The finding that mutations in the TRPC6 gene are
associated with familial forms of FSGS may be used for
genotyping of candidate individuals. Polymorphisms of
TRPC6 may act as a susceptibility factors for renal disease
and may help determine which patients would benefit from
early and intensified therapy. Whereas genotyping assays
have been regularly used as a research tool to screen
patients for the presence of mutations associated with FSGS
and nephrotic syndrome [38], this approach is making it
rather slowly into renal practice. However, with rapid,
reliable, and affordable genetic testing becoming increas-
ingly available, genotyping of candidate patients are likely
to play an increasingly important role in clinical diagnos-
tics. Tests for mutations in the NPHS1 (nephrin), NPHS2
(podocin), and TRPC6 genes are more frequently being
used in daily clinical practice. Early knowledge on TRPC6-
related FSGS risk may enable an earlier therapeutic
intervention. It may also prompt the affected individuals
to adopt a lifestyle aiming to preserve kidney function as
long as possible, such as by adhering to a low-salt diet in an
effort to control blood pressure. Probably even more
relevant downstream mechanisms of dysfunctional TRPC6
channels will be unraveled, thereby facilitating the discov-
ery of novel drugs that control TRPC6 function in the
podocyte [2].
Dual role for TRPC6 in genetic and acquired forms
of proteinuric kidney disease
TRPC6 mutations, although small in terms of numbers of
affected families, provide important novel clues towards the
understanding of hereditary forms of proteinuric glomerular
disease. Moreover, a recent study showed that wildtype
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human proteinuric kidney diseases [39]. An induction of
TRPC6 protein was also observed in experimental in vitro
and in vivo models of acquired glomerular disease. These
results are in line with the hyperactivity of mutated TRPC6
channels in genetic FSGS, pointing to a deleterious effect
of too much TRPC6 activity, whether it stems from a
mutation or from an induced wildtype channel, or both.
Of particular interest is the strong induction of TRPC6
protein in membranous glomerulopathy [39]. Membranous
glomerular disease represents the most common cause of
idiopathic nephrotic syndrome in white adults, accounting
for about one fifth of all cases [40]. Eighty percent of cases
are classified as idiopathic [41], and are often associated
with auto-antibodies to M-type phospholipase A2 receptor
(PLA2R) [42]. In membranous nephropathy, subepithelial
immune deposits form in situ as a result of circulating
antibodies against one or several antigens that remain yet to
be identified in humans [43]. Hand in hand with the
formation of immune deposits goes activation of the
complement, leading to the assembly of C5b-9 membrane
attack complexes on podocyte plasma membranes, which
represents the main culprit for sublethal podocyte injury
and the onset of proteinuria [44]. It has also been reported
that the damage to podocytes mediated by the complement
C5b-9 complex is associated with an activation of phos-
pholipase C and an increase in intracellular calcium [45].
Finally, among the cellular mechanisms leading to protein-
uria in membranous nephropathy are cytoskeletal changes
[46] similar to those observed upon TRPC6 overexpression
[39]. It will therefore be important to study possible
mechanisms of TRPC6 regulation by the complement and
to investigate the downstream effects of elevated TRPC6
activity in membranous disease—particularly now that the
M-type phospholipase A2 receptor (PLA2R) has been
discovered as an antigen for auto-antibodies found in a
wide variety of patients with membranous nephropathy
[42]. Since the influx of extracellular Ca
2+ is tightly
coupled to phospholipase A2 activation in some cell types,
such as C62B glioma cells [47], it will be interesting to see
if the binding of pathological antibodies to PLA2R
facilitates signaling through TRPC6.
What does it all mean for treating patients?
At this time, DNA sequencing and PCR assays are
commercially available to identify TRPC6 mutations. These
allow risk stratification for earlier management and possible
delay of the progression of the disease. The standard
treatment of TRPC6-associated FSGS is still not well
defined, and efforts are mainly focused on the management
of hypertension and proteinuria known to be classical risk
factors predisposing to renal damage and scarring. On the
one hand, blood pressure control has been shown to delay
the progression of many glomerular diseases, especially
when angiotensin converting enzyme (ACE) inhibitors and
angiotensin II receptor blockers (ARBs) are used, both of
which also contribute to decreasing proteinuria, in part even
independently of hemodynamics [48]. On the other hand,
managing the complications of nephrotic syndrome
includes the use of diuretics and lipid-lowering agents,
such as statins [49]. Currently, there is no clinical consensus
on routinely testing steroid-resistant FSGS patients for the
known podocyte gene mutations, but this may change as
new therapies for genetic FSGS become available.
In recent years, many groups have started experimenting
with new methods to target overly active TRPC6. Since
both overly active mutated TRPC6 or induced wildtype
TRPC6 protein cause renal damage, multiple experimental
hypotheses that focus on modifying TRPC6 expression or
blocking TRPC6 channels specifically in podocytes are
currently being investigated [2]. Novel TRPC6 siRNA
coupled with a podocyte-specific delivery system (sham-
porter = sheep anti-mouse podocyte transporter) has already
been shown to significantly decrease TRPC6 protein
expression in podocytes [50]. Other possibilities are
currently being studied in experiments aimed at finding
specific inhibitors of TRPC6 that will not affect other
TRPC subunits such as, for example, TRPC5 or TRPC1,
which are also expressed in podocyte foot processes [20].
This may be a very difficult task, and it might possibly be
easier to utilize non-specific TRPC6 inhibitor with directed
delivery. Profection methods have recently become avail-
able that can transport such inhibitory peptides or even
entire proteins packed in synthetic lipid structures to
specific cells, including podocytes [51]. The uptake of
drug cargo to podocytes might be particularly promising
given the capacity of podocytes for active endo- and
macropinocytosis [52].
While the quest to find the right agent and approach is
currently underway, we need to consider the multiple
subcellular spaces in which TRPC6 operates (Fig. 3). While
a known downstream target of TRPC6 is nuclear factor of
activated T-cells (NFAT) signaling that originates in the cell
body and carries on into the cell nucleus [53], the action of
Ca
2+ in foot processes might stem mainly from SD-
associated TRPC6 protein, with the primary goal to regulate
foot process dynamics. Given this possible spatial separa-
tion of TRPC6 function, a therapeutic goal might be to
neutralize overly active TRPC6 in foot processes while
leaving TRPC6 function in the podocyte cell body and
nucleus unaffected. More studies will better clarify the
possible multiple roles of TRPC6 in podocytes. While these
studies will require some time, we should not forget to test
existing drugs that might be re-purposed for blocking
Pediatr Nephrol (2011) 26:1057–1064 1061TRPC6 or TRPC6-mediated downstream signals in podo-
cytes, such as calcineurin inhibitors. Since a non-T-cell
inhibitory dose might be sufficient to positively affect
podocytes, a low-dose treatment approach could spare
many of the side effects of currently utilized calcineurin
inhibitors in FSGS patients.
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Questions
Answers appear following the reference list.
1. Which is the key cell in the kidney that regulates
filtration?
a) mesangial cell
b) proximal tubular epithelial cell
c) podocyte
d) parietal epithelial cell
e) endothelial cell
2. The podocyte is most similar to ?
a) pericyte
b) vascular smooth muscle cell
c) adipocyte
d) fibroblast
e) none of the above
3. The glomerular slit diaphragm is ?
a) a microvillus
b) an intracellular contact
c) an extension of the GBM
d) a modified adherens junction
e) a classical tight junction
4. TRPC6 is potentially a good drug target because ?
a) it is involved in regulation of the kidney filter
b) it is the main gene mutated in IgA nephropathy
c) it is the TRP channel in polycystic kidney disease
e) none of the above
5. Podocytes are druggable cells because ?
a) they turn over frequently
b) they are exposed to blood and primary urine
c) they display active endo- and macropinocytosis
d) b + c are correct
e) none of the above
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